Equity Overview
Price & Market Data
Price: $2.37
Daily Change: -$0.06 / 2.53%
Daily Range: $2.36 - $2.44
Market Cap: $21,275,276
Daily Volume: 85,037
Performance Metrics
1 Week: -2.87%
1 Month: 0.42%
3 Months: 95.87%
6 Months: 40.24%
1 Year: -2.47%
YTD: 39.41%
Company Details
Employees: 102
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above, and Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.